Nuvalent
Logotype for Nuvalent Inc

Nuvalent (NUVL) investor relations material

Nuvalent 44th Annual J.P. Morgan Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Nuvalent Inc
44th Annual J.P. Morgan Healthcare Conference summary13 Jan, 2026

Strategic vision and approach

  • Focus on precisely targeted therapies for cancer, leveraging chemistry and structure-based drug design expertise.

  • Emphasis on validated kinase targets to accelerate discovery and development.

  • Addressing key challenges: kinase resistance and selectivity to improve durability and tolerability.

  • Building strong relationships with physicians and patient advocates to inform drug design.

  • Portfolio includes programs for ROS1, ALK, and HER2-driven non-small cell lung cancer.

Pipeline progress and clinical data

  • Zidesamtinib (ROS1) and NVL-655 (ALK) have both received FDA Breakthrough Therapy Designation.

  • NDA for zidesamtinib accepted with a PDUFA date in September; NDA for NVL-655 to be submitted in H1 2026.

  • Both drugs show high response rates and durability, including in heavily pretreated and CNS-involved patients.

  • Enrollment in pivotal studies exceeded projections due to strong demand and differentiated profiles.

  • HER2 program (NVL-330) in early clinical development, designed for selectivity and brain penetration.

Market opportunity and commercial strategy

  • Durable responses translate to longer therapy duration, expanding the market size for ROS1 and ALK therapies.

  • ROS1 market could grow to $1.5–2 billion, aligning with ALK market size.

  • ALK market already exceeds $2 billion, with potential for further growth as outcomes improve.

  • Building U.S. commercial infrastructure and preparing for global expansion.

  • Leveraging 15 years of industry experience to optimize launch and market access strategies.

Tactics to expand ROS1/ALK market to target size
How will neladalkib compete in ALK frontline?
What's the long-term vision for HER2 program?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Nuvalent earnings date

Logotype for Nuvalent Inc
Q4 202527 Feb, 2026
Nuvalent
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Nuvalent earnings date

Logotype for Nuvalent Inc
Q4 202527 Feb, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer patients. The company specializes in the creation of small molecule inhibitors that are designed to target specific kinases with high precision. Its leading product candidates include NVL-520, which targets ROS1-positive non-small cell lung cancer, and NVL-655, aimed at addressing ALK-positive cancers. Both candidates are designed to overcome resistance and minimize adverse events associated with existing treatments. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage